SCHEMBL4300233

SCHEMBL4300233

CCCN(CCC)[C@@H](CCCCN)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.46
RNPEP Q9H4A4 1/20 0.44
CPB2 Q96IY4 5/20 0.43
NOD1 Q9Y239 2/20 0.39
GRIK1 P39086 2/20 0.39
GRIK2 Q13002 2/20 0.39
SLC1A2 P43004 2/20 0.39
SLC1A1 P43005 2/20 0.39
GNAI3 P08754 1/20 0.37
GNAO1 P09471 1/20 0.37
GNAI1 P63096 1/20 0.37
SLC6A5 Q9Y345 1/20 0.37
GPR84 Q9NQS5 3/20 0.36
FFAR1 O14842 1/20 0.36
SLC1A3 P43003 1/20 0.36
FOLH1 Q04609 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4300231 1.00 GSR (0.46) GSRRNPEPCPB2NOD1GRIK1
SCHEMBL9634474 0.90 NOD1 (0.49) GSRRNPEPCPB2NOD1GRIK1
SCHEMBL9634471 0.90 NOD1 (0.49) GSRRNPEPCPB2NOD1GRIK1
SCHEMBL30775015 0.88 NOD1 (0.51) GSRCPB2NOD1GRIK1GRIK2
SCHEMBL341674 0.88 NOD1 (0.51) GSRCPB2NOD1GRIK1GRIK2
SCHEMBL1031164 0.88 NOD1 (0.51) GSRCPB2NOD1GRIK1GRIK2
SCHEMBL28077042 0.88 NOD1 (0.51) GSRCPB2NOD1GRIK1GRIK2
SCHEMBL6859337 0.87 GSR (0.50) GSRRNPEPCPB2NOD1FOLH1
SCHEMBL6859332 0.87 GSR (0.50) GSRRNPEPCPB2NOD1FOLH1
SCHEMBL9062119 0.86 NOD1 (0.49) GSRCPB2NOD1GRIK1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250332272-A1 PREPARATION METHOD FOR DRUG LINKER CONJUGATE AND INTERMEDIATE THEREOF MEDILINK THERAPEUTICS SUZHOU CO LTD (CN) 2025-10-30 US disclosed
EP-4534104-A1 PREPARATION METHOD FOR DRUG LINKER CONJUGATE AND INTERMEDIATE THEREOF Medilink Therapeutics (Suzhou) Co., Ltd. (CN) 2025-04-09 EP disclosed
WO-2023231988-A1 PREPARATION METHOD FOR DRUG LINKER CONJUGATE AND INTERMEDIATE THEREOF 苏州宜联生物医药有限公司 2023-12-07 WO disclosed
CN-117143177-A Preparation method of drug connector conjugate and intermediate thereof 苏州宜联生物医药有限公司 2023-12-01 CN disclosed
CN-117143178-A Preparation method of drug connector conjugate and intermediate thereof 苏州宜联生物医药有限公司 2023-12-01 CN disclosed
US-20090264618-A1 Compounds With a Branched Linker ANDRES HERBERT 2009-10-22 US disclosed
EP-1327146-B1 COMPOUNDS WITH A BRANCHED LINKER ROCHE DIAGNOSTICS GMBH (DE) 2005-09-14 EP disclosed
US-20040086943-A1 Coupling agent containing secordary amide groups ROCHE DIAGNOSTICS OPERATIONS, INC. 2004-05-06 US disclosed
EP-1327146-A2 COMPOUNDS WITH A BRANCHED LINKER Roche Diagnostics GmbH (DE) 2003-07-16 EP disclosed
WO-2002027315-A2 COMPOUNDS WITH A BRANCHED LINKER ROCHE DIAGNOSTICS GMBH (DE) 2002-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264618-A1 Compounds With a Branched Linker ZYX, ZFX, BMX GSR 2547/4885RNPEP 490/4885CPB2 1305/4885
US-20040086943-A1 Coupling agent containing secordary amide groups PAICS, BRDT, ERBB2 GSR 3250/4885RNPEP 689/4885CPB2 1696/4885
US-20250332272-A1 PREPARATION METHOD FOR DRUG LINKER CONJUGATE AND INTERMEDIATE THEREOF SI, PAICS, FURIN GSR 4349/4885RNPEP 1371/4885CPB2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.